The goal of this research study is to test the clinical effectiveness of a drug called
infliximab (Remicade) in chronic beryllium disease (CBD). This drug may reduce tumor necrosis
factor-alpha (TNF-a), which is associated with more severe disease and inflammation in the
lung. Receiving infliximab may help with symptoms, and may improve clinical testing data
normally ordered by your doctor, such as breathing tests. Baseline and follow-up testing will
look for improvements in breathing tests (pulmonary function testing), exchange of oxygen in
the lungs (exercise test), chest x ray, and lung inflammation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Maier, Lisa, M.D.
Collaborators:
Centocor, Inc. National Center for Research Resources (NCRR)